<DOC>
	<DOCNO>NCT03086954</DOCNO>
	<brief_summary>This open , single-arm , multicenter 2 phase clinical study treat patient CD19 positive lymphoma infusion patient 's T cell genetically modify express chimeric antigen receptor ( CAR ) bind tumour cell modify express CD19 protein cell surface . The study determine modify T cell help body 's immune system eliminate tumour cell .The trial also study safety treatment CAR-T , long CAR-T cell stay patient 's body impact treatment survival .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety With CAR-T Immunotherapy CD19 Positive Lymphoma</brief_title>
	<detailed_description>This open , single-arm , multicenter 2 phase clinical study evaluate efficacy safety chimeric antigen receptor T cell immunotherapy ( CAR-T ) treatment CD19 positive lymphoma . The study conduct use phaseⅠ/Ⅱdesign study follow sequential phase : part A ( screen , leukapheresis , cell product preparation cytoreductive chemotherapy ) part B ( treatment follow-up ) . The follow-up period participant approximately 35 month final CAR-T infusion . The total duration study expect approximately 3 year . A total 24 patient may enrol period 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1.Age old 16 year old , gender race limit . 2.Pathological diagnosis CD19 express positive recurrent refractory B lymphoma , satisfy follow diagnosis recurrent refractory lymphoma : ( 1 ) According standard solution standardization four course treatment , tumor size &lt; 50 % progression ; ( 2 ) According standard solution treatment complete remission , recurrence original plan national expert consensus recommend secondline get complete remission ( 3 ) Relapse hematopoietic stem cell transplantation . 3.Patients group need lesion available test evaluate disease . 4.ECOG score reach 0 1 point . 5.Patients group White Blood Cell count peripheral blood acuity≥ 1.0 x10^9 / L. 6.Estimated survival time &gt; 90 day . 7.Patients selfknowledge ability , sign inform consent form . 1.Pregnant lactating woman . 2.Uncontrolled infection . 3.HIV infection , hepatitis B C activity period . 4.Patients need longterm immunosuppressive therapy ( Such allergy , autoimmune disease , GVHD , etc . ) 5.Combined activity central nervous system malignant tumor invasion . 6.Abnormal coagulation function , patient severe thrombosis . 7 . Organ failure Heart：class Ⅱ . Liver：class Ⅱ ( Refer Classification Wuhan Conference ( 1983 ) ) . Kidney : The second stage renal insufficiency . Lung : class Ⅱdecreased slightly . Brain : The central nervous system transfer active lesion . 8.Patients participate clinical trial past 30 day participate clinical trial time . 9.Investigator believe patient suitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CD19 positive lymphoma</keyword>
</DOC>